TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03646812

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Reference 1
Description: Glucose contains 50g of available carbohydrates

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Reference 2
Description: Glucose contains 50g of available carbohydrates

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Reference 3
Description: Glucose contains 50g of available carbohydrates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semolina Penne
Description: Semolina Penne contains 50g of available carbohydrates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wholegrain Penne
Description: Wholegrain Penne contains 50g of available carbohydrates
Study: NCT04001777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1252
Description: Multiple dose cohorts, 30 minute IV infusion, weekly for 3 weeks of a cycle with 21days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib Mesylate Tablets
Description: Osimertinib Mesylate Tablets 40mg/80 mg, one time a day until disease progression
Study: NCT02631733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT02962024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Study: NCT01374152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive sensory motor training therapy
Description: training method that emphasis on cognition/ sensation/ and motor movement together train every working day 45 minutes per day for 4 weeks.
Study: NCT01763307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RECONVAL CREAM

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Study: NCT03450811

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal hernia repair
Description: Lichtenstein procedure or laparoscopic method (Total extraperitoneal) inguinal hernia repair
Study: NCT00428714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: Administered orally
Study: NCT01404338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Halobetasol 0.05% ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ointment
Study: NCT00507767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given PO or via PEG tube

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02363049

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Study: NCT03646812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semolina Spaghetti
Description: Semolina Spaghetti contains 50g of available carbohydrates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wholegrain Spaghetti
Description: Wholegrain Spaghetti contains 50g of available carbohydrates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jasmine Rice
Description: Jasmine Rice contains 50g of available carbohydrates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asian Noodles
Description: Asian Noodles contains 50g of available carbohydrates
Study: NCT02785861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: supervision of physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: distance supervised physical activity
Study: NCT02631733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT00456599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1, 8, and 15 of a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin 85mg/m2 will be infused following gemcitabine over approximately 90 minutes on days 1 and 15 of a treatment cycle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: The total dose in a three week treatment block will be 30 Gy in 2.0 Gy fractions.
Study: NCT01182974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: 1 gr of paracetamol PO/PZ/PR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dypirone
Description: 1 gr PO/PZ/PR/IM
Study: NCT03453255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: chidamide, decitabine, homoharringtonine, cytarabine
Study: NCT02096666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 337
Description: Phase 1- AMG 337 150 mg, 200mg and 300 mg orally daily. Additional 150 mg and 200 mg orally twice daily. Phase 2- AMG 337 (dose determined by Phase 1)
Study: NCT02024880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Protective catheter group
Description: The tip of this catheter is protected on insertion of the catheter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional catheter group
Description: A standard embryo catheter
Study: NCT01488292

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RECAP social skills and reading program
Description: weekly individual and group sessions
Study: NCT01192503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rasagiline
Description: 1mg (2 tablets of 0.5mg) at bedtime taken by mouth for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (sugar pill)
Description: 1mg (2 tablets of 0.5mg) taken at bedtime by mouth for 12 weeks
Study: NCT02120170

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colon polypectomy
Study: NCT03876691

Intervention type: OTHER
Intervention: Patients
Description: Patients who are considered as terminally ill and would not benefit from aggressive treatment, who physicians suggest to family about a do-not-resuscitate.

Intervention type: OTHER
Intervention: Physician
Description: The current emergency medical department departments within the preparation of the attending physician
Study: NCT03452904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon
Description: Treatment of in suit coronary lesions with drug-coated balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent
Description: Treatment of in suit coronary lesions with drug-eluting balloon
Study: NCT04338633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional calcium hydroxide paste
Description: Conventional calcium hydroxide paste (Ultracal) will be removed in second visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide nanoparticle
Description: Calcium hydroxide nanoparticle. manufactured in NanoTech. institute, will be removed in second visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Calcium hydroxide with silver nanoparticle
Description: Combined Calcium hydroxide with silver nanoparticle will be removed in second visit.
Study: NCT03263468

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Same sitting PCI with complete revascularization
Description: revascualrization of the non IRA (infarct related artery) of \> 2.0 mm by coronary angioplasty/stenting at the time of primary PCI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staged PCI with complete revsacularization >48 hours pf primary PCI
Description: revascualrization of the non IRA (infarct related artery) of \> 2.0 mm by coronary angioplasty/stenting \>48 hours to 45 days post primary PCI
Study: NCT03697278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smith medical CADDsolis
Description: This group will be monitoring from a network.
Study: NCT04316806

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic (dietary supplement) administrated once daily (u.i.d) for 8 weeks (3 billion cfus per day)

Intervention type: DRUG
Group type: OTHER
Intervention: Rifaximin
Description: Antibiotic rifaximin consisting 400 mg capsules administrated twice daily (b.i.d) for 1week.
Study: NCT04128982

Intervention type: PROCEDURE
Intervention: mobilization of the larynx
Description: Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression in 2 groups: patient in dorsal decubitus or Rapid Airway Management Positioner.
Study: NCT01332188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-170 0.05%
Description: 1 drop in each eye at 3 separate times during a 21 day period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-170 0.1%
Description: 1 drop in each eye at 3 separate times during a 21 day period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-170 0.24%
Description: 1 drop in each eye at 3 separate times during a 21 day period
Study: NCT00769938

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI (percutaneous coronary intervention)
Description: only patients scheduled for PCI can be included tough this intervention would also take place without this study. What we want to study is the difference in outcome after a little change in the antithrombotic treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI (percutaneous coronary intervention)
Description: only patients scheduled for PCI can be included tough this intervention would also take place without this study. What we want to study is the difference in outcome after a little change in the antithrombotic treatment
Study: NCT01326416

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Reconditioning by a trainer
Description: Physical reconditioning sessions begin with a warm-up for five minutes for the type of effort made, and then correspond to a sporting course composed of elements of strength training and / or aerobic exercises and will be completed by a return to simple stretching and general advice on managing their physical life. The duration of each session will be 45 minutes at the beginning of the protocol and then gradually increased over time to achieve 1:30 of total physical activity at the end of protocol.
Study: NCT03016975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards Cardioband System
Description: Transcatheter mitral valve repair with the Edwards Cardioband System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards Cardioband System
Description: Transcatheter mitral valve repair with the Edwards Cardioband System
Study: NCT03967964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone 2.2 g
Description: Vaginal ring with 2.2 grams DHEA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone 1.5 g/Testosterone 25 mg
Description: Vaginal ring with DHEA 1.5 grams/Testosterone 25 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Vaginal ring with 35 mg testosterone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Topical Gel
Description: Gel containing 1% testosterone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dehydroepiandrosterone Oral Capsule
Description: Capsule containing 25 mg DHEA
Study: NCT00967798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100 mg of sitagliptin is taken orally each morning with breakfast. Duration is 12 months or conversion to CF diabetes, whichever comes first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg of sitagliptin is taken orally each morning with breakfast. Duration is 12 months or conversion to CF diabetes, whichever comes first.
Study: NCT03182829

Intervention type: DIAGNOSTIC_TEST
Intervention: DOAC Dipstick
Description: Patients collect a sample of urine for analysis.~publication Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. \[Epub ahead of print\]

Intervention type: DIAGNOSTIC_TEST
Intervention: DOAC Dipstick
Description: Patients collect a sample of urine for analysis.~publication Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. \[Epub ahead of print\]
Study: NCT01994460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Study: NCT03016975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline Directed Medical Therapy
Description: GDMT Only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guideline Directed Medical Therapy
Description: GDMT Only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guideline Directed Medical Therapy
Description: GDMT Only
Study: NCT00633243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Directly Observed Therapy (mDOT)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self-Administered Therapy (SAT)
Study: NCT02042456

Intervention type: DEVICE
Intervention: Digital Breast Tomosynthesis
Description: digital breast tomosynthesis technology

Intervention type: DEVICE
Intervention: Automated Whole Breast Ultrasound
Description: Automated Whole Breast Ultrasound
Study: NCT03547167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PNEUMOVAX™23
Description: 23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOVAX™23
Description: 23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
Study: NCT01446718

Intervention type: BIOLOGICAL
Intervention: Gardasil vaccine
Description: 0.5ml of intramuscular vaccine in three doses
Study: NCT02302157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AST-OPC1
Description: One injection of 2 million or 10 million AST-OPC1 cells, or 2 injections of 10 million AST-OPC1 cells for a total of 20 million cells; cohort dependent
Study: NCT02076594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Powder for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Powder for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Powder for solution for infusion
Study: NCT02042456

Intervention type: DEVICE
Intervention: Full Field Digital Mammography
Study: NCT01808573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Study: NCT01702454

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix Quadrivalent
Description: 1 or 2 doses administered intramuscularly (IM) in deltoid region depending on the priming status

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix Quadrivalent
Description: 1 or 2 doses administered intramuscularly (IM) in deltoid region depending on the priming status
Study: NCT02228551

Intervention type: OTHER
Group type: OTHER
Intervention: Augmented renal clearance Point prevalence study
Description: An 8-hour urine collection was carried out to determine the CrCl8h. Participants were asked to empty the bladder at the start of the collection. From then, patients were asked to collect urine in a recipient during the following 8 hours. If an indwelling transurethral or suprapubic urinary catheter was in situ, the collection bag was emptied at the start of the collection. After 8 hours, total urinary volumes (Uv8h) were measured with a measuring cup and urinary creatinine concentrations were determined by laboratory analysis. Midterm serum creatinine samples were obtained at 4 hours after the start of the urinary collection. Based on these values, CrCl8h was calculated according to the standard formulas and normalized to a body surface area (BSA) of 1.73m².
Study: NCT02390401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure
Description: Prevena (VAC) device at the time of primary closure for a cesarean section, left in place for 5-7 days postoperatively.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard sterile dressing
Description: Standard sterile dressing at the time of primary closure for a cesarean section, left in place for 1-2 days postoperatively.
Study: NCT04762797

Intervention type: OTHER
Intervention: Non
Description: This is a retrospective study, without intervention.

Intervention type: OTHER
Intervention: Non
Description: This is a retrospective study, without intervention.
Study: NCT03596528

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lung biopsy
Description: Each patient will be brought to the operating room and will undergo cryobiopsy and surgical biopsy of the lung sequentially in the same surgical stage.
Study: NCT00994292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT01389544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 200 mg daily (100 mg q12h) orally, Days 1-10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methadone
Description: stable maintenance therapy: 20-120 mg daily single oral morning dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 200 mg daily (100 mg q12h) orally, Days 1-10
Study: NCT00851812

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Standard care monitoring
Study: NCT02076594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Film coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Film coated tablets
Study: NCT03650465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Description: Cognitive-behavioral therapy (CBT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Description: Cognitive-behavioral therapy (CBT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Description: Cognitive-behavioral therapy (CBT)
Study: NCT01332188

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AC-170 0%
Description: 1 drop in each eye at 3 separate times during a 21 day period
Study: NCT01502150

Intervention type: OTHER
Intervention: Data Collection
Description: Information collected from follow-up visits post proton radiation therapy yearly or more often, and test results for at least 10-15 years.

Intervention type: OTHER
Intervention: Dose Distribution Data Collection
Description: Data collection of complete plan information, including dose distribution, beam configuration and images, computed tomography (CT) images acquired on multiple days and 4D CT's for respiratory correlated imaging.
Study: NCT03411564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filming Together to See Ourselves in a New 'Present'
Description: PHASE 0. PRIOR TRAINING 1) Promoting protective assets related to violence together. 10-hour training session with 10-15 secondary school teachers; 2) Identifying our own protective assets against violence. This training activity will be addressed to targeted students. The activity will be carried out in four sessions of 1 hour in duration.~PHASE 1.PRE-PRODUCTION. 1) Participant activity on building story arguments; and 2) Construction of a technical and literary guide to the video capsules.~PHASE 2: PRODUCTION.- 1) Rehearsal of the script developed by each group; 2) Preparation and selection of environment, wardrobe and characterization of the roles and, 3) Filming of the video capsules.~PHASE 3: POST-PRODUCTION.- This phase consists of putting together the short film using the various video capsules.~PHASE 4: DISSEMINATION. A short film exhibition to provide a space where participants can present their video capsules and briefly explain the production process.
Study: NCT03888677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU, epirubicin and cyclophosphamide
Description: Tailored dose escalation of epirubicin and cyclophosphamide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU, epirubicin and cyclophosphamide
Description: Tailored dose escalation of epirubicin and cyclophosphamide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU, epirubicin and cyclophosphamide
Description: Tailored dose escalation of epirubicin and cyclophosphamide.
Study: NCT02251717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily
Study: NCT03905317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injection
Description: Bevacizumab maintenance therapy starts 1-2 months later after the chemotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, and the drug is given every 3 weeks until disease progression or intolerable toxicity occurs.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chest radiation
Description: The patients receive SBRT radiotherapy for the primary (if any) and metastatic lesions or divided radiotherapy with or without concurrent chemotherapy.
Study: NCT00851812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive walking and resistance exercise treatment
Description: Home-based exercise : Progressive walking and resistance program